Halozyme Therapeutics and ViroPharma have signed a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) for the development of a subcutaneous formulation of Cinryze (C1 esterase inhibitor [human]). Halozyme may receive as much as $83 million, with $9 million upfront and potential future milestone payments of $74 million based on clinical and regulatory targets, plus a 10% royalty on future sales. ViroPharma will have exclusivity to C1 esterase inhibiti...